Research Peptide Laws in New Zealand: What Researchers Need to Know

New Zealand researchers working with peptide compounds need a clear understanding of the legal and regulatory framework that governs their use. The distinction between research peptides and pharmaceutical medicines in NZ is important, and the rules around sourcing, supply, and use are defined by several overlapping pieces of legislation. This guide provides an overview of what researchers need to know.

Note: This article provides general informational context for researchers. It does not constitute legal advice. Researchers should seek appropriate legal or regulatory guidance specific to their situation and institution.

The Regulatory Framework in New Zealand

New Zealand regulates medicines and related substances primarily through the Medicines Act 1981 and associated regulations. Medsafe (the New Zealand Medicines and Medical Devices Safety Authority, a business unit of the Ministry of Health) administers this framework.

Under the Medicines Act 1981, a “medicine” is defined as any substance or article prepared or sold for use in the diagnosis, treatment, mitigation, or prevention of disease in humans. The key word here is “use”: a substance is regulated as a medicine based on its intended use and how it is presented, not solely on its chemical composition.

Research peptides that are clearly labelled and supplied for laboratory research purposes only, and that are not presented as suitable for human administration, do not fall within the definition of a medicine under this framework. This is the basis on which research peptide suppliers in New Zealand operate.

The Psychoactive Substances Act 2013

The Psychoactive Substances Act (PSA) 2013 introduced a separate regulatory category for substances with psychoactive properties. Peptides and research compounds that do not produce psychoactive effects are not subject to the PSA framework. However, researchers should be aware of this Act as it relates to the broader regulatory landscape.

The Hazardous Substances and New Organisms Act 1996 (HSNO)

Research chemicals and laboratory substances may also fall under the Hazardous Substances and New Organisms Act 1996, administered by the Environmental Protection Authority (EPA). HSNO classifies substances based on their hazard profile. Most synthetic peptides at research quantities do not carry significant HSNO hazard classifications, but researchers working with larger quantities or novel compounds should check the HSNO register.

Therapeutic Products Act (Forthcoming)

New Zealand is in the process of updating its therapeutic products regulatory framework. The Therapeutic Products Act was passed in 2023 but as of the time of this writing had not yet been fully brought into force. When implemented, this legislation will replace the Medicines Act 1981 and may alter how research compounds are classified and regulated. Researchers and suppliers should monitor Medsafe communications for updates on the implementation timeline.

What “For Research Use Only” Means in Practice

The “for research use only” designation is not merely a disclaimer: it defines the legal context in which research peptides can be supplied and used. In practice, this means:

• Research peptides must not be presented or sold for human or animal therapeutic use.
• Suppliers must not make claims about health benefits, treatment outcomes, or physiological effects in humans.
• Purchasers must use compounds for legitimate research purposes, not for personal administration.
• Compounds must be handled in a manner appropriate for laboratory materials.

Researchers operating within universities, private research institutions, or commercial R&D facilities typically work within ethics frameworks that define appropriate use. If your research involves animal models, additional ethics approval and compliance with the Animal Welfare Act 1999 will be relevant.

Importing Research Peptides into New Zealand

While domestic suppliers reduce the need for importation, some researchers may source compounds internationally. Importing research chemicals into New Zealand requires compliance with Customs and Border Protection requirements. Peptides are not generally controlled substances at research quantities, but customs officials may query shipments that are not well-documented.

Key documentation for import includes:

• A clear description of the compound (chemical name, CAS number where applicable)
• The stated purpose (laboratory research)
• Certificate of analysis confirming the compound identity and purity
• Invoice from the supplier

Using a domestic NZ supplier eliminates import complications entirely. Eterna Peptides supplies all listed compounds from within New Zealand with no customs process required.

Institutional and Ethics Requirements

Beyond the statutory framework, researchers working within institutions will be subject to internal policies governing the acquisition and use of research chemicals. Many New Zealand universities and research institutes require researchers to register chemicals in their institutional management systems and to operate within approved research protocols.

Ethics approval is generally required for research involving human subjects or animal models. Purely in vitro or computational research may not require ethics approval but should still comply with institutional policies on chemical storage, handling, and disposal.

Responsible Research Practice

The research peptide space in New Zealand operates on the basis of responsible self-regulation by suppliers and researchers. Reputable suppliers maintain clear research-use-only marketing, provide full documentation, and do not supply to individuals who indicate intent to use compounds for non-research purposes.

Eterna Peptides supplies all compounds with full COA documentation and clear research-use designation. The COA page provides batch-level purity documentation for all products. The research page provides additional guidance on responsible compound use in a laboratory context.

Summary for New Zealand Researchers

Research peptides in New Zealand are legal to purchase and use for laboratory research purposes. They are not classified as medicines when supplied and used in a research context. Key obligations for researchers include:

• Sourcing from a supplier that clearly designates compounds for research use only
• Using compounds only for legitimate laboratory research purposes
• Complying with institutional policies and ethics requirements relevant to your research
• Maintaining appropriate documentation including COAs, batch records, and research protocols
• Monitoring the evolving regulatory framework, particularly the implementation of the Therapeutic Products Act

For researchers in Auckland, Wellington, Christchurch, or anywhere in New Zealand, Eterna Peptides provides domestic supply of research compounds with full documentation and NZ-based customer support.

---